References of "Diabète & Métabolisme"
     in
Bookmark and Share    
Full Text
Peer Reviewed
See detailChirurgie bariatrique chez le patient diabétique de type 1 : résultats d’une expérience limitée.
FRANCK, Marie ULg; DE FLINES, Jenny ULg; PAQUOT, Nicolas ULg et al

in Diabète & Métabolisme (2013), 39(suppl), 102

Detailed reference viewed: 13 (2 ULg)
Full Text
Peer Reviewed
See detailAllergie systémique à l’insuline: traitement médical ou chirurgical (greffe de pancréas vascularisé).
Leonet, J; RADERMECKER, Régis ULg; Malaise, J et al

in Diabète & Métabolisme (2005), 31

Detailed reference viewed: 9 (1 ULg)
Full Text
Peer Reviewed
See detailAllergie systémique à l'insuline: traitement médical ou chirurgical (greffe de pancréas vascularisé)?
Leonet, J.; RADERMECKER, Régis ULg; Malaise, J. et al

in Diabète & Métabolisme (2005), 31

Detailed reference viewed: 17 (1 ULg)
Full Text
Peer Reviewed
See detailEvaluation de l'exactitude du capteur de glucose CGMS chez des patients hospitalisés
RADERMECKER, Régis ULg; Djakouré, C.; Reach, G. et al

in Diabète & Métabolisme (2002), 28

Evaluation d'un capteur de glucose

Detailed reference viewed: 15 (3 ULg)
Full Text
Peer Reviewed
See detailHBA1c: clinical and biological agreement for standardization of assay methode. Report by the expert of ALFEDIAM (Association de Langue française pour l'étude du diabète et des maladies métaboliques) and SFBC (Société française de Biologie clinique)
Gillery, Pierre; Bordas-Fonfrède, M.; Chapelle, Jean-Paul ULg et al

in Diabète & Métabolisme (1999), 25(3), 283-7

Glycohaemoglobin, and particularly haemoglobin A1c(HbA1c), assays have been used for many years to retrospectively evaluate the glycaemic control of diabetic patients. Cut-off values have been established ... [more ▼]

Glycohaemoglobin, and particularly haemoglobin A1c(HbA1c), assays have been used for many years to retrospectively evaluate the glycaemic control of diabetic patients. Cut-off values have been established for deciding treatment modifications. The techniques used in the laboratories however exhibit varying quality, and all of them are not yet standardized. The consequence is an under-utilization of this test, especially in non-hospital practice. In this context, working groups of Société Française de Biologie Clinique (SFBC), Association de Langue Française pour l'Etude du Diabète et des Maladies Métaboliques (ALFEDIAM) and Société Française d'Endocrinologie (SFE) have met together, in order to analyze the national status, and to propose practical recommendations for implementing a standardization process on the basis of international experiences. It is recommended to exclusively express results as HbA1c percentage, using methods standardized and certified by comparison to reference methods such as those using Diabetes Control and Complications Trial (DCCT) values. Simultaneously, contacts have been established with manufacturers, and the realisation of periodic quality control surveys was encouraged. [less ▲]

Detailed reference viewed: 54 (0 ULg)
Peer Reviewed
See detailComment évaluer la sécrétion insulinique en pratique?
Scheen, A. J.; Paquot, Nicolas ULg; Letiexhe, M. R. et al

in Diabète & Métabolisme (1995), 21(6), 458-64

Detailed reference viewed: 7 (0 ULg)
Peer Reviewed
See detailRetinopathy, but not neuropathy, is influenced by the level of residual endogenous insulin secretion in type 2 diabetes.
Bozet, Marie-Claire ULg; Scheen, André ULg; Gerard, Pascale ULg et al

in Diabète & Métabolisme (1995), 21(5), 353-9

The files of 132 patients with Type 2 diabetes were retrospectively studied to characterize the influence of metabolic control and residual insulin secretion on neuropathy and retinopathy, the two most ... [more ▼]

The files of 132 patients with Type 2 diabetes were retrospectively studied to characterize the influence of metabolic control and residual insulin secretion on neuropathy and retinopathy, the two most frequent degenerative diabetic complications. Patients were classified according to their metabolic control (mean HbA1C either < or > or = 8%; reference values: 3-6%) and residual endogenous insulin secretion (fasting plasma C-peptide levels either < or > or = 0.600 nmol/l). Neuropathy was more frequent in patients with poor metabolic control (32/64 = 50%) than in those adequately controlled (17/68 = 25%; p < 0.005). In both subgroups, the level of endogenous insulin secretion did not influence the prevalence of neuropathy. Retinopathy was less effected than neuropathy by the degree of metabolic control (37.5% in the subgroup with HbA1C > or = 8% v.s. 25% in the subgroup with HbA1C < 8%; p < 0.10), but was influenced by residual insulin secretion. Indeed, in patients with inadequate metabolic control, the prevalence of retinopathy was significantly increased in those with higher endogenous insulin secretion (51.4 versus 20.6%, p < 0.02) and thus probably higher insulin resistance. Furthermore, higher systolic arterial blood pressure was observed in the subgroups with a higher prevalence of retinopathy. Such conclusions were confirmed using multivariate analysis. Thus, in Type 2 diabetes, neuropathy is essentially affected by the degree of metabolic control, whereas retinopathy is also influenced by the level of residual endogenous insulin secretion and the presence of systolic hypertension. [less ▲]

Detailed reference viewed: 6 (0 ULg)
Peer Reviewed
See detailAmylin/islet amyloid polypeptide: biochemistry, physiology, patho-physiology.
Castillo, M. J.; Scheen, André ULg; Lefebvre, Pierre ULg

in Diabète & Métabolisme (1995), 21(1), 3-25

Amylin is a 37 amino-acid peptide mainly produced by the islet beta-cell. Aggregation of amylin is partly responsible for amyloid formation. Amyloid deposits occur both extracellularly and intracellularly ... [more ▼]

Amylin is a 37 amino-acid peptide mainly produced by the islet beta-cell. Aggregation of amylin is partly responsible for amyloid formation. Amyloid deposits occur both extracellularly and intracellularly and may contribute to beta-cell degeneration. Amylin is packed in beta-cell granules and cosecreted with insulin in response to the same stimuli but, unlike other beta-cell products, it is produced from specific a gene on chromosome 12. Basal, plasma amylin concentrations are around 5 pM, and increase fourfold after meals or glucose. Higher levels are found in cases of insulin resistance, obesity, gestational diabetes and in some patients with NIDDM. Low or absent levels are found in insulin-dependent diabetic patients. There are similarities between amylin and non beta-cell peptides such as calcitonin gene related peptides (CGRP). They may bind to the same receptor, determine similar post-receptor phenomena and qualitatively similar actions but with different degree of potency. The actions of amylin are multiple and mostly exerted in the regulation of fuel metabolism. In muscle, amylin opposes glycogen synthesis, activates glycogenolysis and glycolysis (increasing lactate production). Consequently, amylin increases lactate output by muscle and increases the plasma lactate concentration. In fasting conditions, this lactate may serve as a gluconeogenic substrate for the liver, contributing to replenish depleted glycogen stores and to increase glucose production. In non-fasting conditions, lactate can be transformed by liver in triglycerides. It is not clear at present whether amylin actions on the liver are direct or mediated by changes in circulating metabolites. A probably indirect effect of amylin in muscle is to decrease insulin- (or glucose)-induced glucose uptake, which may contribute to insulin resistance. Other actions include inhibition of glucose-stimulated insulin secretion and, in general, actions mimicking CGRP effects. Some of these actions are seen at supraphysiological concentrations. The physiopathological consequences of amylin deficiency, or excess are under active by investigated. [less ▲]

Detailed reference viewed: 38 (1 ULg)
Peer Reviewed
See detailMétabolisme hépatique du glucose après ingestion de fructose chez des sujets obèses non diabétiques et diabétiques non insulinodépendants
PAQUOT, Nicolas ULg; Tappy, L.; Schneiter, ph et al

in Diabète & Métabolisme (1995), 21(suppl),

Detailed reference viewed: 20 (0 ULg)
Peer Reviewed
See detailInteractions entre glucocorticoïdes et sympathomimétiques et sensibilité à l'insuline chez l'homme
PAQUOT, Nicolas ULg; Schneiter, ph; Jéquier, E. et al

in Diabète & Métabolisme (1994), 20(suppl),

Detailed reference viewed: 14 (0 ULg)